Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement

Simple item page
dc.contributor.authorKlimek, L.
dc.contributor.authorJutel, M.
dc.contributor.authorAkdis, C.
dc.contributor.authorBousquet, J.
dc.contributor.authorAkdis, M.
dc.contributor.authorBachert, C.
dc.contributor.authorAgache, I.
dc.contributor.authorAnsotegui, I.
dc.contributor.authorBedbrook, A.
dc.contributor.authorBosnic-Anticevich, S.
dc.contributor.authorCanonica, G. W.
dc.contributor.authorChivato, T.
dc.contributor.authorCruz, A. A.
dc.contributor.authorCzarlewski, W.
dc.contributor.authorGiacco, S. D.
dc.contributor.authorDu, H.
dc.contributor.authorFonseca, J. A.
dc.contributor.authorGao, Y.
dc.contributor.authorHaahtela, T.
dc.contributor.authorHoffmann-Sommergruber, K.
dc.contributor.authorIvancevich, J. C.
dc.contributor.authorKhaltaev, N.
dc.contributor.authorKnol, E. F.
dc.contributor.authorKuna, P.
dc.contributor.authorLarenas-Linnemann, D.
dc.contributor.authorMelen, E.
dc.contributor.authorMullol, J.
dc.contributor.authorNaclerio, R.
dc.contributor.authorOhta, K.
dc.contributor.authorOkamoto, Y.
dc.contributor.authorO'Mahony, Liam
dc.contributor.authorOnorato, G. L.
dc.contributor.authorPapadopoulos, N. G.
dc.contributor.authorPawankar, R.
dc.contributor.authorPfaar, O.
dc.contributor.authorSamolinski, B.
dc.contributor.authorSchwarze, J.
dc.contributor.authorToppila-Salmi, S.
dc.contributor.authorShamji, M. H.
dc.contributor.authorVentura, M. T.
dc.contributor.authorValiulis, A.
dc.contributor.authorYorgancioglu, A.
dc.contributor.authorMatricardi, P.
dc.contributor.authorZuberbier, T.
dc.contributor.authorARIA-MASK Study Group
dc.date.accessioned2020-05-05T08:17:40Z
dc.date.available2020-05-05T08:17:40Z
dc.date.issued2020-04-24
dc.date.updated2020-05-01T09:14:39Z
dc.description.abstractThe current COVID-19 pandemic influences many areas of social life, medical treatments and the way allergy is performed. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on immunological effects on the diseased patient.en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationKlimek, L., Jutel, M., Akdis, C., Bousquet, J., Akdis, M., Bachert, C., Agache, I., Ansotegui, I., Bedbrook, A., Bosnic-Anticevich, S., Canonica, G. W., Chivato, T., Cruz, A. A., Czarlewski, W., Giacco, S. D., Du, H., Fonseca, J. A., Gao, Y., Haahtela, T., Hoffmann-Sommergruber, K., Ivancevich, J. C., Khaltaev, N., Knol, E. F., Kuna, P., Larenas-Linnemann, D., Melen, E., Mullol, J., Naclerio, R., Ohta, K., Okamoto, Y., O'Mahony, L., Onorato, G. L., Papadopoulos, N. G., Pawankar, R., Pfaar, O., Samolinski, B., Schwarze, J., Toppila-Salmi, S., Shamji, M. H., Ventura, M. T., Valiulis, A., Yorgancioglu, A., Matricardi, P., Zuberbier, T. and the ARIA-MASK Study Group (2020) 'Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement', Allergy. doi: 10.1111/all.14336en
dc.identifier.doi10.1111/all.14336en
dc.identifier.eissn1398-9995
dc.identifier.issn0105-4538
dc.identifier.journaltitleAllergyen
dc.identifier.urihttps://hdl.handle.net/10468/9896
dc.language.isoenen
dc.publisherJohn Wiley & Sons, Inc.en
dc.rights© 2020, John Wiley & Sons, Inc. This is the peer reviewed version of the following article: Klimek, L., Jutel, M., Akdis, C., Bousquet, J., Akdis, M., Bachert, C., Agache, I., Ansotegui, I., Bedbrook, A., Bosnic-Anticevich, S., Canonica, G. W., Chivato, T., Cruz, A. A., Czarlewski, W., Giacco, S. D., Du, H., Fonseca, J. A., Gao, Y., Haahtela, T., Hoffmann-Sommergruber, K., Ivancevich, J. C., Khaltaev, N., Knol, E. F., Kuna, P., Larenas-Linnemann, D., Melen, E., Mullol, J., Naclerio, R., Ohta, K., Okamoto, Y., O'Mahony, L., Onorato, G. L., Papadopoulos, N. G., Pawankar, R., Pfaar, O., Samolinski, B., Schwarze, J., Toppila-Salmi, S., Shamji, M. H., Ventura, M. T., Valiulis, A., Yorgancioglu, A., Matricardi, P., Zuberbier, T. and the ARIA-MASK Study Group (2020) 'Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement', Allergy, doi: 10.1111/all.14336, which has been published in final form at https://doi.org/10.1111/all.14336. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.en
dc.subjectCOVID-19en
dc.subjectAllergen-specific immunotherapyen
dc.subjectAITen
dc.titleHandling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statementen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
all.14336.pdf
Size:
8.69 MB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medicine - Journal Articles
APC Microbiome Ireland - Journal Articles
Microbiology - Journal Articles